Back to Results
First PageMeta Content
Research / Science / Food and Drug Administration / Pharmaceutical industry / Bioethics / Tegaserod / New Drug Application / Placebo / Clinical trial / Medicine / Clinical research / Pharmacology


Transcript of FDA Press Conference on the Discontinued Marketing of Zelnorm FTS HHS FDA Moderator: Susan Cruzan March 30, [removed]:30 am CT
Add to Reading List

Open Document

File Size: 65,27 KB

Share Result on Facebook

Company

Wall Street Journal / FDA Press / USA Today / Novartis Pharmaceuticals / Reuters / Gastroenterology / /

Country

Switzerland / United States / /

Event

FDA Phase / Product Recall / Product Issues / /

IndustryTerm

credentialed media / treatment of women with irritable bowel syndrome / /

MedicalCondition

severe chest pain / strokes / chronic constipation / unstable angina / heart attacks / angina / constipation / gastrointestinal disorders / shortness of breath / stroke / ischemic colitis / heart attack / dizziness / irritable bowel syndrome / /

Organization

office of New Drugs / Food and Drug Administration / office of Surveillance and Epidemiology / office of Surveillance / office of New Drug / FDA / Center for Drug Evaluation and Research / FDA’s office of Public Affairs / /

Person

Anna Matthews / Julia Korvick / Susan Cruzan / Epidemiology / Rita Rubin / John LaPook / John Jenkins / Julie Beitz / Joyce Korvick / Liza Richwine / Jon LaPook / Gerald Dal Pan / /

Position

CT Coordinator / first speaker / Coordinator / Director / Deputy Director Division of Gastroenterology Products and Dr. Gerald Dal Pan / Director / Deputy Director of the Division / Deputy Director of the Division of Products / /

Product

Permax / drug / Zelnorm / New Drug / /

ProvinceOrState

Indiana / /

PublishedMedium

USA Today / Wall Street Journal / /

SocialTag